Ainos (AIMD) Insider Ownership : 76.25 % (As of Dec. 11, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Ainos Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ainos's insider ownership is 76.25%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ainos's Institutional Ownership is 1.44%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ainos's Float Percentage Of Total Shares Outstanding is 77.03%.

Ainos Insider Ownership Historical Data

The historical data trend for Ainos's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ainos Insider Ownership Chart

Ainos Historical Data

The historical data trend for Ainos can be seen below:

	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30
Insider Ownership	75.10	75.10	75.10	75.10	75.55	75.38	74.44	76.25	76.25	76.25

Ainos Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Ainos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108

Website

https://www.ainos.com

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Executives

Meng Lin Sung	officer: Chief Financial Officer	8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee	director	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc	10 percent owner	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei	director	10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai	director, officer: Chairman, CEO, CFO	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai	director	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang	director	5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang	director	NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin	other: EVP - OPERATIONS	2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu	officer: Chief Financial Officer	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu	director	9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai	director	105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen	director	1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen	officer: VP, CFO	4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore	director	402 FISH HATCHERY ROAD, HAMILTON MT 59840